TFF Pharmaceuticals, Inc.
TFFPDelisted Mar 6, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001733413
TFF Pharmaceuticals, Inc. was delisted on Mar 6, 2025; its insiders filed their last Form 4 on Jul 8, 2024; 23 institutions reported holding it in 13F filings for Q3 2024, worth $1.48M in total; no superinvestor held it.
13F holders, Q3 2024
Institutional positions in TFF Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
TFFP is no longer listed, so this page shows Q3 2024. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 23
- +3 vs. Q2 2024
- Shares held
- 733.8K
- +97.4K (+15.3%) vs. Q2 2024
- Total value
- $1.48M
- +$418.7K (+39.6%) vs. Q2 2024
- New holders
- 4
- 5 more added
- Sold out
- 1
- 3 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TFFP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 3 | $0 |
| Q4 2024 | 4 | $196 |
| Q3 2024 | 23 | $1.48M |
| Q2 2024 | 21 | $1.07M |
| Q1 2024 | 19 | $2.12M |
| Q4 2023 | 23 | $2.45M |
| Q3 2023 | 41 | $4.04M |
| Q2 2023 | 33 | $3.02M |
| Q1 2023 | 36 | $4.80M |
| Q4 2022 | 41 | $7.52M |
| Q3 2022 | 45 | $17.2M |
| Q2 2022 | 45 | $23.7M |
| Q1 2022 | 43 | $27.1M |
| Q4 2021 | 51 | $41.1M |
| Q3 2021 | 54 | $45.1M |
| Q2 2021 | 60 | $54.5M |
| Q1 2021 | 63 | $96.1M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding TFF Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Danske Bank A/S | 1 | $2 | 0.00% | +1 | New |
| Bank of America Corp | 28 | $56 | 0.00% | +5+21.7% | Added |
| Morgan Stanley | 32 | $64 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 40 | $80 | 0.00% | 00.0% | Unchanged |
| HM Payson & Co | 60 | $121 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 61 | $123 | 0.00% | 00.0% | Unchanged |
| Raleigh Capital Management Inc. | 91 | $183 | 0.00% | 00.0% | Unchanged |
| Gen-Wealth Partners Inc | 100 | $251 | 0.00% | 00.0% | Unchanged |
| ORG Partners LLC | 540 | $1.08K | 0.00% | −200−27.0% | Reduced |
| UBS Group AG | 675 | $1.36K | 0.00% | −60−8.2% | Reduced |
| University of Texas/Texas Am Investment Managment Co | 882 | $1.77K | 0.00% | 00.0% | Unchanged |
| Nordwand Advisors, LLC | 1,000 | $2.01K | 0.00% | +1,000 | New |
| Tower Research Capital LLC (TRC) | 1,948 | $3.92K | 0.00% | −2,984−60.5% | Reduced |
| BlackRock, Inc. | 7,186 | $14.4K | 0.00% | +7,186 | New |
| Nwam LLC | 10,240 | $20.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 12,136 | $24.4K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 13,579 | $27.3K | 0.00% | +13,579 | New |
| Renaissance Technologies LLC | 20,497 | $41.2K | 0.00% | +5,720+38.7% | Added |
| Geode Capital Management, LLC | 27,999 | $56.3K | 0.00% | +6,201+28.4% | Added |
| DRW Securities, LLC | 40,000 | $80.4K | 0.00% | 00.0% | Unchanged |
| Westside Investment Management, Inc. | 75,264 | $151.3K | 0.03% | +24,773+49.1% | Added |
| Armistice Capital, LLC | 228,000 | $458.3K | 0.01% | +42,305+22.8% | Added |
| Carlson Capital L P | 293,460 | $589.9K | 0.36% | 00.0% | Unchanged |
| Royal Bank of Canada | 0 | $0 | 0.00% | −156−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |